Mr. Elliot McKerr reports

HYTN RECEIVES GMP CERTIFICATES FOR THE UNITED STATES, BERMUDA AND ISRAEL

HYTN Innovations Inc. has received digital good manufacturing practice certificates from Health Canada, confirming the GMP compliance of its Kelowna-based manufacturing facility. Issued under HYTN's drug establishment licence, these certificates specifically acknowledge the company's GMP status for the United States, Bermuda and Israel.

The certificates, requested by HYTN in February, are important for drug registrations in jurisdictions where they apply. They also provide assurance in regions with limited regulatory frameworks, validating that HYTN's production processes meet GMP standards. Notably, the company's DEL enables it to fabricate, package and label non-sterile pharmaceuticals containing cannabis and psilocybin, positioning HYTN at the forefront of international markets looking to expand their pharmaceutical offerings.

"By demonstrating GMP compliance in markets that require it, HYTN is well positioned to support new drug registrations, facilitate clinical trials, and offer contract manufacturing for both cannabis and psilocybin-based pharmaceuticals," said Jason Broome, chief operating officer of HYTN. "Our continued commitment to GMP manufacturing strengthens our ability to evaluate global opportunities while driving value for partners and stakeholders alike."

While HYTN is already active in commercial projects across Canada, the United Kingdom, Germany and Australia, the company is also exploring expansions into additional markets. Securing GMP certificates for the United States, Bermuda and Israel underscores HYTN's progress in advancing GMP drug development and reaffirms its leadership in high-quality, compliant manufacturing practices to fuel international growth.

About HYTN Innovations Inc.

HYTN is a pharmaceutical company specializing in the formulation, manufacturing, marketing and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

We seek Safe Harbor.